Objective: The cell cycle profile test is suggested to be an independent prognostic indicator for breast cancer patients. To further clarify the prognostic value, we applied this to breast cancer patients treated with postoperative 5-fluorouracil-based chemotherapy. Methods: A total of 153 breast cancer patients, who were treated with postoperative 5-fluorouracil-based chemotherapies, were randomly selected. Specific activities of cyclindependent kinases 1 and 2 in the tumor samples were analyzed. Patients were divided into three categories (low, intermediate or high risk) based on cell cycle profile analysis. Results: The proportions of the cell cycle profile categories were 39% for low risk, 10% for intermediate risk and 45% for high risk, respectively. Although the cell cycle profile test did not show a significant predictive power for relapse-free survival (high vs. low risk; P ¼ 0.052), the cell cycle profile categories were significant prognostic factors in a subgroup of 98 patients with fewer than three involved nodes (high vs. low risk, P ¼ 0.004). Multivariate analyses also indicated that a cell cycle profile parameter (high vs. low risk) was an independent prognostic indicator from the number of involved nodes and clinical stage in this subgroup (hazard ratio ¼ 2.46, P ¼ 0.01). Interestingly, the prognostic power of the cell cycle profile test was significant in 75 patients treated with oral 5-fluorouracil derivatives alone (hazard ratio ¼ 6.29 for high vs. low risk, P ¼ 0.02). Conclusions: These findings suggest that the cell cycle profile test is useful for predicting a higher risk of relapse in patients treated with postoperative 5-fluorouracil-based chemotherapy.
INTRODUCTION
Tumor cell proliferation is one of the major hallmarks of tumor biology and has been investigated for the prediction of prognosis as well as sensitivity to chemotherapy in patients with breast cancer (1) . The Ki-67-labeling index, a well-recognized proliferation marker, was recommended for clinical use at the St. Gallen International Consensus Conference in 2009 (2) : 'Markers of proliferation and specifically Ki-67-labelling index were considered important for the determination of prognosis and, importantly, to indicate the potential value of the addition of chemotherapy to patients with receptor-positive disease'.
Cyclin-dependent kinases (CDKs) play important roles in cell cycle progression. We hypothesized that a CDK activity assay would provide valuable information not only for monitoring tumor growth but also for predicting patient prognosis. A method enabling simultaneous analysis of the CDK protein expression and kinase activities have been established and named the cell cycle profile (C2P) test (3) . To clarify the clinical significance of the C2P test, 284 frozen tissues from Japanese breast cancer patients were analyzed in our previous study (4) . Combination analysis of CDK1SA (specific activity, SA; kinase activity/protein expression) and CDK2SA enabled the classification of breast cancers into high-and low-risk groups in node-negative patients (hazard ratio [HR] 6.73; P , 0.001). We then defined an equation to calculate the risk score for relapse (C2P RS). The cut-offs were successfully clarified in another study with frozen breast cancer specimens from 352 Dutch patients (5) .
To further clarify the prognostic value of the C2P test, we applied this test to patients with operable breast cancer treated postoperatively with 5-fluorouracil (FU)-based chemotherapy in a single institute.
PATIENTS AND METHODS

PATIENTS
A total of 153 breast cancer patients were randomly selected as the study subjects (Table 1 ). All had been treated with postoperative adjuvant 5-FU-based chemotherapies, such as classical cyclophosphamide/methotrexate/5-fluorouracil (CMF) therapy (cyclophosphamide [CPA], methotrexate, 5-FU: 100 mg/day CPA given orally on days 1 -14 followed by a 14-day rest, 40 mg/m 2 methotrexate given intravenously on days 1 and 8 and 500 mg/m 2 5-FU given intravenously on days 1 and 8), or oral 5-FU derivative therapy (Table 2) between 1990 and 2003 at Kawasaki Medical School Hospital, and their frozen tumor samples were stored in our tumor bank. Endocrine therapy was also given to 110 patients (72%); 86 patients received tamoxifen or toremifene alone, 2 patients aromatase inhibitor alone, 10 patients tamoxifen or toremifene followed by aromatase inhibitor, 7 patients luteinizing-hormone-releasing hormone (LH-RH) agonist alone and 5 patients LH-RH agonist plus tamoxifen.
The median patient age was 53 years (range: 22-83); 70% had stage I or IIA disease according to the American Joint Committee on Cancer (AJCC, 5th edition); 72% received a 
C2P ANALYSIS
Specific activities (SAs) of CDK1 and CDK2 were determined by in vitro kinase and protein expression assays using fresh-frozen tumor materials (3 Â 3 Â 3 mm for each) as described (3, 4) . In brief, a lysate of frozen material was applied to the wells of a 96-well PVDF filter plate (Millipore, MA, USA). The expression of CDKs was detected quantitatively by sequential reactions with primary anti-CDK antibodies, biotinylated anti-rabbit antibodies and fluorescein-labeled streptavidin. To measure kinase activity, each CDK molecule was immunoprecipitated from the tissue lysate. The thiophosphate of ATP-gS was transferred to the protein substrate during the on-bead kinase reaction. The introduced thiophosphate was labeled further with 5-iodoacetamidofluorescein and blotted onto a well of the filter plate. Kinase activity was determined by measuring the fluorescence intensity of the well. CDK SA was calculated as CDK kinase activity (aU/ml lysate) divided by its corresponding CDK expression (eU/ml lysate). Both aU (CDK activity unit) and eU (CDK expression unit) were defined as the equivalent expression and activity of 1 ng of recombinant active CDK molecule, respectively.
Patients were classified into three categories, low, intermediate and high risk, based on the C2P risk score (C2P RS) given by the following equations composed of two elements, Equation (1) for the ratio of CDK2SA relative to CDK1SA (CDK2SA/CDK1SA) and Equation (2) for CDK1SA. Cut-off values for C2P RS were determined as 1.47 for highrisk tumors and 0.45 for low (5) .
BIOMARKERS AND HISTOLOGIC PARAMETERS ER and PR status was determined by immunohistochemical (IHC) analyses using anti-ER monoclonal antibody 1D5 (Dako, Tokyo, Japan) and anti-PR monoclonal antibody 1A6 (Leica Microsystems GmbH, Wetzlar, Germany), respectively. The cut-offs for receptor positivity were 1% (2). HER2 expression was examined by HercepTest (DakoCytomation, Carpinteria, CA, USA). According to the criteria of the HecepTest, scores 0 and 1þ were considered negative, and scores 2þ and 3þ were considered positive (6). Tumor cell proliferation was evaluated using Ki-67 labeling index (7). The Mib1 antibody (Dako, Tokyo, Japan) was used for Ki-67 protein detection. The Ki-67 labeling index was defined as the fraction of tumor cells showing any nuclear Ki-67 immunoreactivity. At least 500 tumor cells were analyzed on each tissue spot to determine the Ki-67 labeling index. Ki-67 labeling index ,20% was considered as low level. IHC intrinsic subtypes were defined as follows: ERþ and/or PRþ (hormone receptor [HR]þ) HER22,HRþHER2þ, HR-HER2þ and triple negative (HR2HER22) (8) . Tumors were classified into histological subtypes according to the General Classification of the Japanese Breast Cancer Society (9) . The American Joint Committee on Cancer (AJCC, 5th edition) stage and lymph node status were collected from the medical records. A validated nuclear grading system based on nuclear atypia and mitotic counts was used (10) .
STATISTICAL ANALYSIS
Differences between the C2P risk categories with regard to clinicopathological characteristics were examined using the x2 test. Because 13 patients with hormone receptor-negative or uncategorized tumors had received endocrine therapy, they were excluded from the survival analyses. RFS was calculated with the Kaplan -Meier method, and the differences Jpn J Clin Oncol 2011;41 (6) 741
were assessed with the log-rank test. The Cox proportional hazards model was used for both univariate and multivariate analyses. Test results were considered significant at P , 0.05. (Table 3 , P , 0.001). Most cases of HR2HER2þ and triple-negative subtypes were categorized into the C2P high-risk group, but the HRþ subtypes were proportionally categorized by the C2P test. 
RESULTS
RESULTS OF THE C2P TEST
UNIVARIATE ANALYSIS
The C2P test did not show a significant predictive power for RFS (Fig. 1 , high vs. low risk; P ¼ 0.052). In contrast, no relapse was observed in low-and intermediate-risk groups in a subgroup of node-negative patients (Fig. 2 , n ¼ 47, high vs. low risk; P ¼ 0.034). In addition, the C2P test showed a strong prognostic significance in the subgroup of 98 patients with fewer than three involved nodes (Fig. 3 , high vs. low risk; P ¼ 0.004). The prognostic power of the C2P test was significant in 75 patients treated with oral 5-FU derivatives alone as chemotherapy (Fig. 4 , high vs. low risk; P ¼ 0.006). In this analysis, we excluded four patients whose C2P category data were unavailable, three patients whose ER or PR data were unavailable and five patients with ER-and PR-negative tumors treated with endocrine therapy. In contrast, the C2P test showed no significant prognostic power in 54 patients RFS rates according to CDK-based risk in breast cancer patients with fewer than three involved lymph nodes (n ¼ 98). The C2P test showed strong prognostic significance in this subgroup of patients. In particular, patients categorized into the C2P high-risk group showed a significantly poorer prognosis than those categorized into the low-risk group (P ¼ 0.004). Figure 4 . RFS rates according to CDK-based risk in breast cancer patients postoperatively treated with oral 5-FU derivatives alone (n ¼ 75). The C2P test showed strong prognostic significance in this subgroup of patients. In particular, patients categorized into the C2P high-risk group showed a significantly poorer prognosis than those categorized into the low-risk group (P ¼ 0.006). Jpn J Clin Oncol 2011;41(6) 743 treated with CMF therapy (data not shown, high vs. low risk; P ¼ 0.935).
To further clarify the significance of the C2P test, RFS was analyzed using Cox proportional hazards model according to the C2P risk category in each intrinsic subtype and in nuclear grade 2 tumors. As shown in Table 4 , the prognostic power of the C2P test was significant in patients with tumors of HRþHER22 subtype but neither tumors of the other subtypes nor nuclear grade 2 tumors. It may be possible that the C2P test did not show a significant prognostic power in the other subtypes and nuclear grade 2 tumors because of a small sample size.
MULTIVARIATE ANALYSIS
The Cox proportional hazards model revealed that nodal status was a significant prognostic factor for RFS but not C2P categories in all patients tested (Table 5) ; however, the C2P test was a significant prognostic factor in a subgroup of 98 patients with fewer than three involved nodes (Table 5 ; overall, P ¼ 0.01; HR ¼ 6.56 for high vs. low risk, P ¼ 0.01). Multivariate analyses of RFS also indicated that the C2P parameter was an independent and better prognostic indicator (HR ¼ 2.46, P ¼ 0.01) than nodal status (P ¼ 0.26) or HER2 status (P ¼ 0.21) in this subgroup. Interestingly, the prognostic power of the C2P test was significant in 75 patients treated with oral 5-FU derivatives alone (overall, P ¼ 0.01; HR ¼ 6.29 for high vs. low risk, P ¼ 0.02).
Multivariate analyses of RFS also indicated that the C2P parameter was an independent and better prognostic indicator (P ¼ 0.01) than nodal status (P ¼ 0.15) or tumor size (P ¼ 0.32) in this subgroup. No significant difference in terms of tumor size, nodal status and clinical stage was observed between the group of patients treated with oral 5-FU derivatives and the group of patients treated with CMF therapy.
DISCUSSION
Our previous studies have shown that CDK-based risk determined by evaluating CDK1SA and CDK2SA by the C2P test was strongly associated with clinical outcome, especially for node-negative breast cancer patients (4, 5) . We consider that CDK-based risk has potential as a new prognostic factor independent of conventional risk factors; however, these studies were retrospective and the study subjects included breast cancer patients postoperatively treated with various chemotherapies. Therefore, to further clarify the prognostic value of the C2P test, we applied it to breast cancer patients treated with postoperative 5-FU-based chemotherapy in this study.
Postoperative 5-FU-based chemotherapies, such as oral 5-FU derivatives or CMF therapy, were commonly used in Japan between the 1990s and early 2000s. Recently, the results of the ACET-BC trial and NSAS-BC trial conducted in Japan have indicated that postoperative adjuvant therapy (11, 12) . Oral anticancer drugs, such as oral 5-FU derivatives, may offer benefits in terms of convenience, ease of administration and compliance. These findings suggest that postoperative 5-FU-based chemotherapies may be useful in a certain subset of breast cancer patients; however, it could be speculated that postoperative chemotherapies with anthracyclines and/or taxanes may be more effective than 5-FU-based chemotherapies in the other subset of breast cancer patients. Therefore, we consider that it might be preferable to distinguish a subset of breast cancer patients with a high risk of relapse during or after 5-FU-based chemotherapies. Such a subset of patients should be treated with stronger chemotherapies, such as anthracycline-and/or taxane-based chemotherapies. Both CDK1 and CDK2 play important roles in cell cycle progression and cell proliferation and are expected to be associated with tumor aggressiveness. As shown in Tables 4  and 5 , patients with breast tumors categorized as the C2P high-risk group are likely to have a high nuclear grade, and ER-negative and/or PR-negative breast tumors. In addition, breast tumors of the triple-negative subtype or HR2HER2þ subtype were more likely to be categorized as the C2P highrisk group. These findings suggest that the C2P test can select patients with aggressive breast cancers. It should be noted that no relapse was observed in patients categorized into the low-or intermediate-risk group with breast cancer of the triple-negative subtype or HR2HER2þ subtype. It is possible that the C2P test can distinguish a subset of patients with less aggressive triple-negative or HR2HER2þ breast tumors and may assist in the suitable selection of chemotherapeutic agents. Further studies are clearly needed to clarify this hypothetical issue.
Although the C2P test did not show a significant predictive power for relapse in all patients tested in this study ( Fig. 1 and Table 5 ), it was a significant and independent prognostic factor in a subgroup of 98 patients with fewer than three involved nodes or in a subgroup of 75 patients treated with oral 5-FU derivatives alone Figs 3 and 4 and Table 5 ). These findings suggest that the C2P test is more useful for predicting a risk of relapse in patients with nodenegative or a few involved lymph nodes. This coincides with the finding of our previous study (4) . It could be speculated that relapse depends not only on tumor aggressiveness but also on the extent of tumor involvement in axillary lymph nodes.
A cell proliferation marker, the Ki-67-labeling index and multi-gene assays, such as the OncotypeDX test and MammaPrint test, have been intensively investigated to realize personalized medicine in the management of breast cancer patients in the past decade (13, 14) . We have developed the C2P test for this purpose. According to the results of this study and our previous studies, the C2P test may be useful to select patients with early breast cancer at a high risk of relapse during or after various standard postoperative therapies. More effective treatment strategies should be offered to such high-risk patients. However, the C2P test has been retrospectively evaluated in breast cancer patients postoperatively treated with non-randomized systemic therapies. To clarify the clinical usefulness of the C2P test, prospective randomized clinical trials or retrospective studies using breast cancer samples from patients entered into prospective randomized clinical trials comparing standard postoperative therapy plus or minus certain chemotherapy should be performed in the near future.
There are some advantages and limitations of the C2P test for the management of breast cancer patients. With regard to its advantages, this test needs only a very small sample (minimum 8 mm 3 ), and the rate of uninformative cases is relatively low (only 3% in this study, Table 3 ). Moreover, this test is much cheaper (H. Ishihara, personal communication) than the OncotypeDX test or MammaPrint test. With regard to its limitations, this test has never been prospectively clarified and its prognostic function has never been compared with the OncotypeDX test or MammaPrint test. In addition, this test showed significant prognostic power only in breast cancer patients with fewer than three involved nodes in this study. The C2P test might provide little prognostic information for breast cancer patients with multiple involved nodes. Indications for the C2P test should be re-evaluated before clinical use.
In conclusion, the C2P test is an independent and better prognostic indicator than nodal status in patients with breast cancer and fewer than three involved nodes treated with adjuvant 5-FU-based chemotherapy. This suggests that the C2P test could be useful for predicting patients with a high risk of relapse, who should be treated with stronger adjuvant methods. Further clinical studies are needed to clarify the prognostic and predictive values of the C2P test.
